Womens Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy

Summary

GBI Research, a leading business intelligence provider, has released its latest research, Womens Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy, which provides insights into the womens health therapeutics market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts. It provides an in-depth analysis of the major diseases, and includes coverage of menopause, postmenopausal osteoporosis, endometriosis, infertility, and female contraceptives. The report provides in-depth analysis of the drivers and barriers that affect the global womens health market, and analyzes the markets for womens health disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), and Japan. The report also analyzes the womens health therapeutics market in India, China and Australia. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global market.

In 2011, the womens health therapeutics market was estimated to be worth $18.8 billion. GBI Research forecasts the market to grow at a Compound Annual Growth Rate (CAGR) of 2.7% between 2011 and 2018, to record a sales value of $22.7 billion in 2018. The patent expiries of blockbusters such as Evista, the Premarin family, Forteo, Mirena, Boniva, Actonel, Gonal-F and others during the forecast period are expected to slow down the market growth for the womens health therapeutics market. The launch of novel molecules like Elagolix and Odanacatib in the late stage pipeline will drive the market in the forecast period.

The womens health therapeutics market R&D pipeline shows promising molecules. The current treatment options for womens disorders are limited due to lack of safety. The unmet need in the womens disorders market is attracting the pharmaceutical companies to invest in R&D programs. Increased focus is seen on therapy areas such as menopause, female sexual dysfunction and infertility.

Scope

- Annualized market data for the womens health disorders market from 2003 to 2011, with forecasts to 2018.
- Analysis of the leading therapeutic segments, including menopause, postmenopausal osteoporosis, endometriosis, infertility, and the female contraceptives market.
- Analysis of the womens health therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the womens health therapeutics market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer Inc., Eli Lilly and Company, F. Hoffman-La Roche Ltd., Merck, Bayer and Warner Chilcott Plc.
- Key M&A activities and licensing agreements that took place in the years 2010 to 2012 in the womens health therapeutics market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Develop market entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by